Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 3/2017

Open Access 01-06-2017 | REVIEW ARTICLE

MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications

Authors: Nicoline W. E. van den Berg, Makiri Kawasaki, Wouter R. Berger, Jolien Neefs, Eva Meulendijks, Anke J. Tijsen, Joris R. de Groot

Published in: Cardiovascular Drugs and Therapy | Issue 3/2017

Login to get access

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with pronounced morbidity and mortality. Its prevalence, expected to further increase for the forthcoming years, and associated frequent hospitalizations turn AF into a major health problem. Structural and electrical atrial remodelling underlie the substrate for AF, but the exact mechanisms driving this remodelling remain incompletely understood. Recent studies have shown that microRNAs (miRNA), short non-coding RNAs that regulate gene expression, may be involved in the pathophysiology of AF. MiRNAs have been implicated in AF-induced ion channel remodelling and fibrosis. MiRNAs could therefore provide insight into AF pathophysiology or become novel targets for therapy with miRNA mimics or anti-miRNAs. Moreover, circulating miRNAs have been suggested as a new class of diagnostic and prognostic biomarkers of AF. However, the origin and function of miRNAs in tissue and plasma frequently remain unknown and studies investigating the role of miRNAs in AF vary in design and focus and even present contradicting results. Here, we provide a systematic review of the available clinical and functional studies investigating the tissue and plasma miRNAs in AF and will thereafter discuss the potential of miRNAs as biomarkers or novel therapeutic targets in AF.
Appendix
Available only for authorised users
Literature
1.
Ball J, Carrington MJ, McMurray JJV, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–24.PubMedCrossRef
2.
Chen LY, Shen W-K. Epidemiology of atrial fibrillation: a current perspective. Hear Rhythm Off J Hear Rhythm Soc. 2007;4:S1–6.CrossRef
3.
Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–68.PubMedCrossRef
4.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)developed with the special contribution of the Europea. Eur Heart J 2016;:ehw210.
5.
Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterisation, and clinical implication. 2016.
6.
Singh JP, Morady F. Patient selection and classification for atrial fibrillation ablation: thinking beyond duration. Hear Rhythm. 2009;6:1522–5.CrossRef
7.
8.
Smit MD, Van Gelder IC. New treatment options for atrial fibrillation: towards patient tailored therapy. Heart. 2011;97:1796–802.PubMedCrossRef
9.
van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255–60.PubMedPubMedCentralCrossRef
10.
11.
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;2008:102–14.CrossRef
12.
Luo X, Yang B, Nattel S. MicroRNAs and atrial fibrillation: mechanisms and translational potential. Nat Rev Cardiol. 2015;12:80–90.PubMedCrossRef
13.
14.
van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–32.PubMedPubMedCentralCrossRef
15.
Girmatsion Z, Biliczki P, Bonauer A, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. Hear Rhythm Off J Hear Rhythm Soc. 2009;6:1802–9.CrossRef
16.
Qi X-Y, Huang H, Ordog B, et al. Fibroblast inward-rectifier potassium current upregulation in profibrillatory atrial remodeling. Circ Res. 2015;116:836–45.PubMedCrossRef
17.
Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol. 2012;107:278.PubMedCrossRef
18.
Cardin S, Guasch E, Luo X, et al. Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure. Circ Arrhythm Electrophysiol. 2012;5:1027–35.PubMedCrossRef
19.
Duisters RF, Tijsen AJ, Schroen B, et al. miR-133 and miR-30 Regulate Connective Tissue Growth Factor. Circ Res 2009;104.
20.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18282.
21.
van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012;11.
22.
Weckbach LT, Grabmaier U, Clauss S, et al. MicroRNAs as a diagnostic tool for heart failure and atrial fibrillation. Curr Opin Pharmacol. 2016;27:24–30.PubMedCrossRef
23.
Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105:10513–8.PubMedPubMedCentralCrossRef
24.
Weber JA, Baxter DH, Zhang S, et al. The MicroRNA Spectrum in 12 body fluids. Clin Chem. 2010;56.
25.
Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035–9.PubMedCrossRef
26.
Fichtlscherer S, De Rosa S, Fox H, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res. 2010;107:677–84.PubMedCrossRef
27.
D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J. 2010;31:2765–73.PubMedPubMedCentralCrossRef
28.
Devaux Y, Mueller M, Haaf P, et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J Intern Med. 2015;277:260–71.PubMedCrossRef
29.
Wang G-K, Zhu J-Q, Zhang J-T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J. 2010;31:659–66.PubMedCrossRef
30.
McManus DD, Lin H, Tanriverdi K, et al. Relations between circulating microRNAs and atrial fibrillation: data from the Framingham Offspring Study. Hear Rhythm Off J Hear Rhythm Soc. 2014;11:663–9.CrossRef
31.
Harling L, Lambert J, Ashrafian H, et al. Elevated serum microRNA 483-5p levels may predict patients at risk of post-operative atrial fibrillation. Eur J Cardio-Thoracic Surg Off J Eur Assoc Cardio-Thoracic Surg Published Online First: 2016.
32.
Yamac AH, Kucukbuzcu S, Ozansoy M, et al. Altered expression of micro-RNA 199a and increased levels of cardiac SIRT1 protein are associated with the occurrence of atrial fibrillation after coronary artery bypass graft surgery. Cardiovasc Pathol Off J Soc Cardiovasc Pathol. 2016;25:232–6.CrossRef
33.
Slagsvold KH, Rognmo O, Høydal M, et al. Remote ischemic preconditioning preserves mitochondrial function and influences myocardial microRNA expression in atrial myocardium during coronary bypass surgery. Circ Res. 2014;114:851–9.PubMedCrossRef
34.
Krogstad LEB, Slagsvold KH, Wahba A. Remote ischemic preconditioning and incidence of postoperative atrial fibrillation. Scand Cardiovasc J SCJ. 2015;49:117–22.PubMedCrossRef
35.
Maesen B, Nijs J, Maessen J, et al. Post-operative atrial fibrillation: a maze of mechanisms. Europace. 2012;14.
36.
Goren Y, Meiri E, Hogan C, et al. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol. 2014;113:976–81.PubMedCrossRef
37.
Liu Z, Zhou C, Liu Y, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One. 2012;7:1–9.
38.
Liu T, Zhong S, Rao F, et al. Catheter ablation restores decreased plasma miR-409-3p and miR-432 in atrial fibrillation patients. Eur Eur Pacing, Arrhythmias, Card Electrophysiol J Work Groups Card Pacing, Arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2016;18:92–9.
39.
40.
McManus DD, Tanriverdi K, Lin H, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). Hear Rhythm Off J Hear Rhythm Soc. 2015;12:3–10.CrossRef
41.
Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91.
42.
Choudhury A, Chung I, Blann AD, et al. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation. J Am Coll Cardiol. 2007;49:1957–64.PubMedCrossRef
43.
44.
Cooley N, Cowley MJ, Lin RCY, et al. Influence of atrial fibrillation on microRNA expression profiles in left and right atria from patients with valvular heart disease. Physiol Genomics. 2012;44:211–9.PubMedCrossRef
45.
Lu Y, Zhang Y, Wang N, et al. MicroRNA-328 contributes to adverse electrical remodeling in atrial fibrillation. Circulation. 2010;122:2378–87.PubMedCrossRef
46.
Liu H, Qin H, Chen G, et al. Comparative expression profiles of microRNA in left and right atrial appendages from patients with rheumatic mitral valve disease exhibiting sinus rhythm or atrial fibrillation. J Transl Med. 2014;12:90.PubMedPubMedCentralCrossRef
47.
Schotten U, Dobrev D, Platonov PG, et al. Current controversies in determining the main mechanisms of atrial fibrillation. J Intern Med. 2016;279:428–38.PubMedCrossRef
48.
Andrade J, Khairy P, Dobrev D, et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114:1453–68.PubMedCrossRef
49.
Nattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63:2335–45.PubMedCrossRef
50.
Heijman J, Voigt N, Nattel S, et al. Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114
51.
Tamargo J, Caballero R, Gomez R, et al. Cardiac electrophysiological effects of nitric oxide. Cardiovasc Res. 2010;87:593–600.PubMedCrossRef
52.
Reilly SN, Liu X, Carnicer R, et al. Up-regulation of miR-31 in human atrial fibrillation begets the arrhythmia by depleting dystrophin and neuronal nitric oxide synthase. Sci Transl Med. 2016;8:340ra74.PubMedPubMedCentralCrossRef
53.
Nishi H, Sakaguchi T, Miyagawa S, et al. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS One. 2013;8:e73397.PubMedPubMedCentralCrossRef
54.
Morishima M, Iwata E, Nakada C, et al. Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K(+) channel, IK.ACh. Circ J Off J Japanese Circ Soc. 2016;80:1346–55.
55.
Watson CJ, Gupta SK, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17:405–15.PubMedPubMedCentralCrossRef
56.
Liu H, Chen G, Liang M, et al. Atrial fibrillation alters the microRNA expression profiles of the left atria of patients with mitral stenosis. BMC Cardiovasc Disord. 2014;14:10.PubMedPubMedCentralCrossRef
57.
Soeki T, Matsuura T, Bando S, et al. Relationship between local production of microRNA-328 and atrial substrate remodeling in atrial fibrillation: J Cardiol Published Online First; 2016.
58.
Cañón S, Caballero R, Herraiz-Martínez A, et al. miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: implications win human chronic atrial fibrillation. J Mol Cell Cardiol. 2016;99:162–73.PubMedCrossRef
59.
Barana A, Matamoros M, Dolz-Gaitón P, et al. Chronic atrial fibrillation increases microRNA-21 in human atrial myocytes decreasing L-type calcium current. Circ Arrhythm Electrophysiol. 2014;7:861–8.PubMedCrossRef
60.
Pandit SV, Berenfeld O, Anumonwo JMB, et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J. 2005;88:3806–21.PubMedPubMedCentralCrossRef
61.
Dobrev D, Graf E, Wettwer E, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K+ current (IK,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced IK,ACh and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104:2551–7.PubMedCrossRef
62.
Kakimoto Y, Tanaka M, Kamiguchi H, et al. MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart. Int J Cardiol. 2016;211:43–8.PubMedCrossRef
63.
Jia X, Zheng S, Xie X, et al. MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model. PLoS One. 2013;8:e85639.PubMedPubMedCentralCrossRef
64.
Christ T, Wettwer E, Ravens U. Letter by Christ et al regarding article, "Angiotensin II potentiates the slow component of delayed rectifier K+ current via the AT1 receptor in Guinea pig atrial Myocytes&quot. Circulation. 2006;114:e565.PubMedCrossRef
65.
Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med. 2007;13:486–91.PubMedCrossRef
66.
Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129:303–17.PubMedCrossRef
67.
Terentyev D, Belevych AE, Terentyeva R, et al. miR-1 overexpression enhances Ca2+ release and promotes cardiac Arrhythmogenesis by targeting PP2A regulatory subunit B56 and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res. 2009;104:514–21.PubMedPubMedCentralCrossRef
68.
Luo X, Pan Z, Shan H, et al. MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest. 2013;123:1939–51.PubMedPubMedCentralCrossRef
69.
70.
Xiao J, Liang D, Zhang Y, et al. MicroRNA expression signature in atrial fibrillation with mitral stenosis. Physiol Genomics. 2011;43:655–64.PubMedCrossRef
71.
Morishima M, Iwata E, Nakada C, et al. Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K(+) channel, IK.ACh. Circ J. 2016;80:1346–55.PubMedCrossRef
72.
Voigt N, Trausch A, Knaut M, et al. Left-to-right atrial inward rectifier potassium current gradients in patients with paroxysmal versus chronic atrial fibrillation. Circ Arrhythmia Electrophysiol. 2010;3:472–80.CrossRef
73.
Dobrev D, Friedrich A, Voigt N, et al. The G protein-gated potassium current IK,ACh Is constitutively active in patients with chronic atrial fibrillation. Circulation. 2005;112:3697–706.PubMedCrossRef
74.
Ling T-Y, Wang X-L, Chai Q, et al. Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. Hear Rhythm Off J Hear Rhythm Soc. 2013;10:1001–9.CrossRef
75.
Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010;3:499–506.PubMedCrossRef
76.
Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55:2330–42.PubMedCrossRef
77.
Gaspo R, Bosch RF, Bou-Abboud E, et al. Tachycardia-induced changes in Na+ current in a chronic dog model of atrial fibrillation. Circ Res. 1997;81:1045–52.PubMedCrossRef
78.
Ellinor PT, Nam EG, Shea MA, et al. Cardiac sodium channel mutation in atrial fibrillation. Hear Rhythm. 2008;5:99–105.CrossRef
79.
Zhao Y, Huang Y, Li W, et al. Post-transcriptional regulation of cardiac sodium channel gene SCN5A expression and function by miR-192-5p. Biochim Biophys Acta. 1852;2015:2024–34.
80.
Hove-Madsen L, Llach A, Bayes-Genís A, et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation. 2004;110:1358–63.PubMedCrossRef
81.
Voigt N, Li N, Wang Q, et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+−Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125:2059–70.PubMedPubMedCentralCrossRef
82.
Li N, Chiang DY, Wang S, et al. Ryanodine receptor-mediated calcium leak drives progressive development of an atrial fibrillation substrate in a transgenic mouse model. Circulation. 2014;129:1276–85.PubMedPubMedCentralCrossRef
83.
Harada M, Luo X, Murohara T, et al. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ Res. 2014;114:689–705.PubMedCrossRef
84.
Nattel S, Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J. 2012;33.
85.
Vest JA, Wehrens XHT, Reiken SR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation. 2005;111.
86.
Harada M, Luo X, Qi XY, et al. Transient receptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation. 2012;126:2051–64.PubMedPubMedCentralCrossRef
87.
Chiang DY, Kongchan N, Beavers DL, et al. Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release. Circ Arrhythm Electrophysiol. 2014;7:1214–22.PubMedPubMedCentralCrossRef
88.
Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.PubMedCrossRef
89.
Krul SPJ, Berger WR, Smit NW, et al. Atrial fibrosis and conduction slowing in the left atrial appendage of patients undergoing thoracoscopic surgical pulmonary vein isolation for atrial fibrillation. Circ Arrhythmia Electrophysiol. 2015;8.
90.
Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96.
91.
Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004;90:400–5.PubMedPubMedCentralCrossRef
92.
Xu J, Cui G, Esmailian F, et al. Atrial extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation. 2004;109.
93.
94.
Lin CS, Pan CH. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci. 2008;65:1489–508.PubMedCrossRef
95.
Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.PubMedCrossRef
96.
Adam O, Zimmer C, Hanke N, et al. Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice. J Mol Cell Cardiol. 2015;85:140–50.PubMedCrossRef
97.
He X, Zhang K, Gao X, et al. Rapid atrial pacing induces myocardial fibrosis by down-regulating Smad7 via microRNA-21 in rabbit. Heart Vessels Published Online First: 2016.
98.
Huang Z, Chen X-J, Qian C, et al. Signal transducer and activator of transcription 3/MicroRNA-21 feedback loop contributes to atrial fibrillation by promoting atrial fibrosis in a rat sterile pericarditis model. Circ Arrhythm Electrophysiol. 2016;9.
99.
Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.PubMedCrossRef
100.
Patrick DM, Montgomery RL, Qi X, et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest. 2010;120:3912–6.PubMedPubMedCentralCrossRef
101.
Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 2012;93:573–82.PubMedCrossRef
102.
Xiong Q, Zhong Q, Zhang J, et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res. 2012;11:2078–90.PubMedCrossRef
103.
Dawson K, Wakili R, Ordög B, et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation. 2013;127:1466–75. 1475-28.PubMedCrossRef
104.
105.
Li H, Li S, Yu B, et al. Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. Mol Med Rep. 2012;5:1457–60.PubMed
106.
Slagsvold KH, Johnsen AB, Rognmo O, et al. Comparison of left versus right atrial myocardium in patients with sinus rhythm or atrial fibrillation - an assessment of mitochondrial function and microRNA expression. Physiol Rep 2014;2.
107.
Shan H, Zhang Y, Lu Y, et al. Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res. 2009;83:465–72.PubMedCrossRef
108.
Wang J, Wang Y, Han J, et al. Integrated analysis of microRNA and mRNA expression profiles in the left atrium of patients with nonvalvular paroxysmal atrial fibrillation: role of miR-146b-5p in atrial fibrosis. Hear Rhythm Off J Hear Rhythm Soc. 2015;12:1018–26.CrossRef
109.
Wang J, Song S, Xie C, et al. MicroRNA profiling in the left atrium in patients with non-valvular paroxysmal atrial fibrillation. BMC Cardiovasc Disord. 2015;15:97.PubMedPubMedCentralCrossRef
110.
van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316:575–9.PubMedCrossRef
111.
112.
113.
Montgomery RL, Hullinger TG, Semus HM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011;124:1537–47.PubMedPubMedCentralCrossRef
114.
Slagsvold KH, Johnsen AB, Rognmo O, et al. Mitochondrial respiration and microRNA expression in right and left atrium of patients with atrial fibrillation. Physiol Genomics. 2014;46:505–11.PubMedCrossRef
115.
Shen MJ, Choi E-K, Tan AY, et al. Neural mechanisms of atrial arrhythmias. Nat Rev Cardiol. 2012;9:30–9.CrossRef
116.
117.
Chen P-S, Chen LS, Fishbein MC, et al. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114:1500–15.PubMedPubMedCentralCrossRef
118.
Deneke T, Chaar H, de Groot JR, et al. Shift in the pattern of autonomic atrial innervation in subjects with persistent atrial fibrillation. Hear Rhythm. 2011;8:1357–63.CrossRef
119.
Zhang Y, Zheng S, Geng Y, et al. MicroRNA profiling of atrial fibrillation in canines: miR-206 modulates intrinsic cardiac autonomic nerve remodeling by regulating SOD1. PLoS One. 2015;10:e0122674.PubMedPubMedCentralCrossRef
120.
121.
Kim D-J, Linnstaedt S, Palma J, et al. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J Mol Diagn. 2012;14:71–80.PubMedPubMedCentralCrossRef
122.
Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006;25:6220–7.PubMedCrossRef
123.
Masè M, Grasso M, Avogaro L, et al. Selection of reference genes is critical for miRNA expression analysis in human cardiac tissue. A focus on atrial fibrillation. Sci Rep. 2017;7:41127.PubMedPubMedCentralCrossRef
124.
Creemers EE, Tijsen AJ, Pinto YM. Circulating MicroRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483–95.PubMedCrossRef
125.
126.
Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast–derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest. 2014;124:2136–46.PubMedPubMedCentralCrossRef
127.
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108:5003–8.PubMedPubMedCentralCrossRef
128.
Turchinovich A, Tonevitsky AG, Cho WC, et al. Check and mate to exosomal extracellular miRNA: new lesson from a new approach. Front Mol Biosci. 2015;2:11.PubMedPubMedCentralCrossRef
129.
130.
131.
132.
Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting MicroRNA. N Engl J Med. 2013;368:1685–94.PubMedCrossRef
133.
Elmén J, Lindow M, Schütz S, et al. LNA-mediated microRNA silencing in non-human primates. Nature. 2008;452:896–9.PubMedCrossRef
134.
Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537–41.PubMedCrossRef
135.
Li Y-D, Hong Y-F, Yusufuaji Y, et al. Altered expression of hyperpolarization-activated cyclic nucleotide-gated channels and microRNA-1 and -133 in patients with age-associated atrial fibrillation. Mol Med Rep. 2015;12:3243–8.PubMedPubMedCentral
136.
Torrado M, Franco D, Lozano-Velasco E, et al. A MicroRNA-transcription factor blueprint for early atrial Arrhythmogenic remodeling. Biomed Res Int. 2015;2015:263151.PubMedPubMedCentralCrossRef
137.
Li H, Li S, Yu B, et al. Expression of miR-133 and miR-30 in chronic atrial fibrillation in canines. Mol Med Rep. 2012;5:1457–60.PubMed
Metadata
Title
MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
Authors
Nicoline W. E. van den Berg
Makiri Kawasaki
Wouter R. Berger
Jolien Neefs
Eva Meulendijks
Anke J. Tijsen
Joris R. de Groot
Publication date
01-06-2017
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 3/2017
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-017-6736-z

Other articles of this Issue 3/2017

Cardiovascular Drugs and Therapy 3/2017 Go to the issue

SHORT COMMUNICATION

The Role of MKP-1 in Insulin-Induced Cardioprotection

ORIGINAL ARTICLE

Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial

ORIGINAL ARTICLE

Argatroban Attenuates Diabetic Cardiomyopathy in Rats by Reducing Fibrosis, Inflammation, Apoptosis, and Protease-Activated Receptor Expression

REVIEW ARTICLE

Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role

ORIGINAL ARTICLE

Primary Care Physician Perspectives on Barriers to Statin Treatment

ORIGINAL ARTICLE

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits